论文部分内容阅读
为了促进创新型青年人才的成长,支持中国神经内科临床医师的研究工作,规范“缺血性卒中/TIA”抗血小板药物的规范化应用,探索抗血小板治疗临床研究的新方向,由深圳信立泰药业股份有限公司支持,《中国卒中杂志》社设立“缺血性卒中/TIA抗血小板治疗临床研究基金”项目。现将有关事项通知如下:
In order to promote the growth of innovative young talents, we support the research work of Chinese neurologists and standardize the standardized application of “anti-ischemic stroke / TIA” antiplatelet drugs to explore the new direction of antiplatelet therapy clinical research. Li Tai Pharmaceutical Co., Ltd. support, “China Stroke Magazine” establishment of “ischemic stroke / TIA Antiplatelet Therapy Clinical Research Fund ” project. The relevant matters are hereby notified as follows: